Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations

References

• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsDepartment of Health and Human Services Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdfAccessed January 27, 2015
   Google Scholar
• European AIDS Clinical SocietyGuidelines Clinical Management and Treatment of HIV Infected Adults in Europe. 7.1112014 Available at: http://www.eacsociety.org/Portals/0/GUIDELINES/English%20PDF%20-%20Version%207.1.pdfAccessed January 27, 2015
   Google Scholar
• CrucianiMMengoliCMalenaMVirological efficacy of abacavir: systematic review and meta-analysisJ Antimicrob Chemother201469123169318025074854
   PubMed Web of Science ®Google Scholar
• RokxCFibrianiAvan de VijverDAfor the AIDS Therapy Evaluation in the Netherlands (ATHENA) National Observational CohortIncreased virological failure in naïve HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch Nationwide ATHENA CohortClin Infect Dis201560114315325273080
   PubMed Web of Science ®Google Scholar
• FordNHillAVitoriaMMillsEJComparative efficacy of lamivudine and emtricitabine: comparing the results of randomized trials and cohortsClin Infect Dis201560115415625273083
   PubMed Web of Science ®Google Scholar
• FordNShubberZHillAComparative efficacy of lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trialsPLoS One20138e7998124244586
   PubMed Web of Science ®Google Scholar
• MallalSNolanDWittCAssociation between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirLancet2002359930872773211888582
   PubMed Web of Science ®Google Scholar
• HetheringtonSHughesARMostellerMGenetic variations in HLA-B region and hypersensitivity reactions to abacavirLancet200235993121121112211943262
   PubMed Web of Science ®Google Scholar
• MallalSPhillipsECarosiGHLA-B*5701 screening for hypersensitivity to abacavirN Engl J Med2008358656857918256392
   PubMed Web of Science ®Google Scholar
• The DAD Study GroupClass of antiretroviral drugs and the risk of myocardial infarctionN Engl J Med2007356171723173517460226
   PubMed Web of Science ®Google Scholar
• SabinCAWormSWWeberRD:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaborationLancet200837196221417142618387667
   PubMed Web of Science ®Google Scholar
• Strategies for Management of Anti-Retroviral Therapy/INSIGHTDAD Study GroupsUse of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patientsAIDS20082214F17F2418753925
   PubMed Web of Science ®Google Scholar
• WormSWSabinCWeberRRisk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) studyJ Infect Dis2010201331833020039804
   PubMed Web of Science ®Google Scholar
• AbergJARibaudoHCardiac risk: not so simpleJ Infect Dis2010201331531720039805
   PubMed Web of Science ®Google Scholar
• GeorgeELucasGMNadkarniGNFineDMMooreRAttaMGKidney function and the risk of cardiovascular events in HIV-1-infected patientsAIDS201024338739420019575
   PubMed Web of Science ®Google Scholar
• DeeksJJDinnesJD’AmicoREvaluating non-randomised intervention studiesHealth Technol Assess2003727iiix117314499048
   PubMedGoogle Scholar
• BrothersCHHernandezJECutrellAGRisk of myocardial infarction and abacavir therapy: no increased risk across 52 Glaxo Smith Kline sponsored clinical trials in adult subjectsJ Acquir Immune Defic Syndr2009511202819282778
   PubMed Web of Science ®Google Scholar
• CrucianiMZanichelliVSerpelloniGAbacavir use and cardiovascular disease events: a meta-analysis of published and unpublished dataAIDS201125161993200421716077
   PubMed Web of Science ®Google Scholar
• DingXAndraca-CarreraECooperCNo association of abacavir use with myocardial infarction: findings of an FDA meta-analysisJ Acquir Immune Defic Syndr201261444144722932321
   PubMed Web of Science ®Google Scholar
• LangSMary-KrauseMCotteLClinical Epidemiology Group of the French Hospital Database on HIV. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4Arch Intern Med2010170141228123820660842
   PubMedGoogle Scholar
• BedimoRJWestfallAODrechslerHVidiellaGTebasPAbacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy eraClin Infect Dis2011531849121653308
   PubMed Web of Science ®Google Scholar
• RibaudoHJBensonCAZhengYfor the ACTG A5001/ALLRT Protocol TeamNo risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRTClin Infect Dis201152792994021427402
   PubMed Web of Science ®Google Scholar
• AbergJACardiovascular complications in HIV management: past, present, and futureJ Acquir Immune Defic Syndr2009501546419295335
   PubMed Web of Science ®Google Scholar
• MoyleGJStellbrinkHJCompstonJ96-week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naïve, HIV-1-infected adults: ASSERT studyAntivir Ther201318790591323899468
   PubMed Web of Science ®Google Scholar
• SaxPETierneyCCollierACAbacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapyN Engl J Med2009361232230224019952143
   PubMed Web of Science ®Google Scholar
• SmithKYPatelPFineDRandomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatmentAIDS200923121547155619542866
   PubMed Web of Science ®Google Scholar
• PappaKHernandezJHaBAbacavir/lamivudine shows robust virologic responses in ART-naïve patients for baseline (BL) viral loads of >100,000 c/mL and <100,000 c/mL by endpoint used in ACTG5202Abstracts of the Seventeenth International AIDS ConferenceMexico City2008 Abstract THAB0304
   Google Scholar
• TanDHChanKRaboudJComparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naïve HIV-infected patients initiating therapyJ Acquir Immune Defic Syndr2011581384621709570
   PubMed Web of Science ®Google Scholar
• WalmsleySLAntelaAClumeckNDolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionN Engl J Med2013369191807181824195548
   PubMed Web of Science ®Google Scholar
• PowderlyWGIntegrase inhibitors in the treatment of HIV-1 infectionJ Antimicrob Chemother20106512248520852268
   PubMed Web of Science ®Google Scholar
• DelelisOCarayonKSaibADeprezEMouscadetJFIntegrase and integration: biochemical activities of HIV-1 integraseRetrovirology2008511419091057
   PubMed Web of Science ®Google Scholar
• HazudaDJFelockPWitmerMInhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cellsScience2000287545364665010649997
   PubMed Web of Science ®Google Scholar
• MesplèdeTQuashiePKZanichelliVWainbergMAIntegrase strand transfer inhibitors in the management of HIV-positive individualsAnn Med201446312312924579911
   PubMed Web of Science ®Google Scholar
• HicksCGulickRMRaltegravir: the first HIV type 1 integrase inhibitorClin Infect Dis200948793193919231980
   PubMed Web of Science ®Google Scholar
• SteigbigelRTCooperDATepplerHLong-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trialsClin Infect Dis201050460561220085491
   PubMed Web of Science ®Google Scholar
• SteigbigelRTCooperDAKumarPNRaltegravir with optimized background therapy for resistant HIV-1 infectionN Engl J Med2008359433935418650512
   PubMed Web of Science ®Google Scholar
• LennoxJLDeJesusELazzarinASafety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLancet2009374969279619647866
   PubMed Web of Science ®Google Scholar
• RockstrohJKLennoxJLDeJesusELong-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMRKClin Infect Dis201153880781621921224
   PubMed Web of Science ®Google Scholar
• EronJJCooperDASteigbigelRTEfficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsLancet Infect Dis201313758759623664333
   PubMed Web of Science ®Google Scholar
• MarkowitzMNguyenBYGotuzzoESustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naïve patients with HIV-1 infectionJ Acquir Immune Defic Syndr200952335035619648823
   PubMed Web of Science ®Google Scholar
• MarkowitzMNguyenBYGotuzzoERapid and durable anti-retroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection: results of a 48-week controlled studyJ Acquir Immune Defic Syndr200746212513317721395
   PubMed Web of Science ®Google Scholar
• SaxPEDeJesusEMillsACo-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus coformulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeksLancet201237998352439244822748591
   PubMed Web of Science ®Google Scholar
• ZolopaASaxPEDeJesusEA randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resultsJ Acquir Immune Defic Syndr20136319610023392460
   PubMed Web of Science ®Google Scholar
• DeJesusERockstrohJKHenryKCo-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialLancet201237998352429243822748590
   PubMed Web of Science ®Google Scholar
• ShahBMSchaferJPrianoJSquiresKECobicistat: a new boost for the treatment of human immunodeficiency virus infectionPharmacotherapy201333101107111623471741
   PubMed Web of Science ®Google Scholar
• Gilead Sciences IncStribild (elvitegravir/cobicistat/tenofovir/emtricitabine) [package insert]Foster City, CA2012
   Google Scholar
• MespledeTQuashiePKWainbergMAResistance to HIV integrase inhibitorsCurr Opin HIV AIDS2012740140822789986
   PubMed Web of Science ®Google Scholar
• van LunzenJMaggioloFArribasJOnce daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naïve adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trialLancet Infect Dis201212211111822018760
   PubMed Web of Science ®Google Scholar
• StellbrinkHReynesJLazzarinADolutegravir in antiretroviral- naïve adults with HIV-1: 96-week results from a randomized dose-ranging studyAIDS2013271771177823807273
   PubMed Web of Science ®Google Scholar
• WalmsleySAntelaAClumeckNDolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infectionN Engl J Med2013369191807181824195548
   PubMed Web of Science ®Google Scholar
• RaffiFRachlisAStellbrinkHJOnce-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyLancet2013381986873574323306000
   PubMed Web of Science ®Google Scholar
• RaffiFJaegerHQuiros-RoldanEOnce-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trialLancet Infect Dis2013131192793524074642
   PubMed Web of Science ®Google Scholar
• ClotetBFeinbergJvan LunzenJOnce-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b studyLancet201438399362222223124698485
   PubMed Web of Science ®Google Scholar
• CahnPPozniakALMingroneHDolutegravir vs raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING studyLancet2013382989370070823830355
   PubMed Web of Science ®Google Scholar
• EronJJClotetBDurantJSafety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir resistant HIV type 1 infection: 24-week results of the VIKING studyJ Infect Dis2013207574074823225901
   PubMed Web of Science ®Google Scholar
• CastagnaAMaggioloFPencoGDolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studyJ Infect Dis2014210335436224446523
   PubMed Web of Science ®Google Scholar
• Fernandez-MonteroJVBarreiroPLabargaPDe MendozaCSorianoVDolutegravir, abacavir and lamivudine as HIV therapyExpert Opin Pharmacother20141571051105724754315
   PubMed Web of Science ®Google Scholar
• RaffiFPozniakAWainbergMHas the time come to abandon efavirenz for first-line antiretroviral therapy?J Antimicrob Chemother20146971742174724603962
   PubMed Web of Science ®Google Scholar
• OsterholzerDAGoldmanMDolutegravir: a next-generation integrase inhibitor for treatment of HIV infectionClin Infect Dis201459226527124723281
   PubMed Web of Science ®Google Scholar
• TemesgenZTalwaniRRizzaSADolutegravir, an HIV integrase inhibitor for the treatment of HIV infectionDrugs Today (Barc)201450171424524102
   PubMed Web of Science ®Google Scholar
• ReeseMJSavinaPMGenerauxGTIn vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitorDrug Metab Dispos201341235336123132334
   PubMed Web of Science ®Google Scholar
• KoteffJBorlandJChenSA phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjectsBr J Clin Pharmacol201375499099622905856
   PubMed Web of Science ®Google Scholar
• MaggiPMontinaroVRusconiSThe problem of renal function monitoring in patients treated with the novel antiretroviral drugsHIV Clin Trials201415879124947532
   PubMed Web of Science ®Google Scholar
• MaletIGimferrer ArriagaLArteseANew raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitorsJ Antimicrob Chemother20146982118212224710029
   PubMed Web of Science ®Google Scholar
• HurtCBSebastianJHicksCBEronJJResistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009–2012Clin Infect Dis201458342343124145878
   PubMed Web of Science ®Google Scholar
• MesplèdeTQuashiePKWainbergMAResistance to HIV integrase inhibitorsCurr Opin HIV AIDS20127540140822789986
   PubMed Web of Science ®Google Scholar
• BlancoJLVargheseVRheeSYGatellJMShaferRWHIV-1 integrase inhibitor resistance and its clinical implicationsJ Infect Dis201120391204121421459813
   PubMed Web of Science ®Google Scholar
• OliveiraM1MesplèdeTQuashiePKMoïsiDWainbergMAResistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitorsAIDS201428681381924463394
   PubMed Web of Science ®Google Scholar
• Rodriguez-RosadoRJimenez-NacherISorianoVVirological failure and adherence to antiretroviral therapy in HIV-infected patientsAIDS1998129111211139662214
   PubMed Web of Science ®Google Scholar
• BangsbergDRCharleboisEDGrantRMHigh levels of adherence do not prevent accumulation of HIV drug resistance mutationsAIDS200317131925193212960825
   PubMed Web of Science ®Google Scholar
• MaggioloFRavasioLRipamontiDSimilar adherence rates favour different virologic outcomes for patients treated with non-nucleoside analogues or protease inhibitorsClin Infect Dis200540115816315614706
   PubMed Web of Science ®Google Scholar
• BangsbergDLess than 95% adherence to nonnucleoside reverse transcriptase inhibitor therapy can lead to viral suppressionClin Infect Dis200643793994116941380
   PubMed Web of Science ®Google Scholar
• ShahBWalsheLSapleDGAdherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, IndiaClin Infect Dis20074491235124417407045
   PubMed Web of Science ®Google Scholar
• MaggioloFAiroldiMKleinloogHDEffect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patientsHIV Clin Trials20078528229217956829
   PubMed Web of Science ®Google Scholar
• BangsbergDRAcostaEPGuptaRAdherence-resistance relationship for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitnessAIDS200620222323116511415
   PubMed Web of Science ®Google Scholar
• BangsbergDRPorcoTCKagayCModelling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimatesJ Infect Dis2004190116216515195256
   PubMed Web of Science ®Google Scholar
• MaggioloFRipamontiDAriciCSimpler regimens may enhance adherence to antiretrovirals in HIV infected patientsHIV Clin Trials20023537137812407486
   PubMedGoogle Scholar
• TrottaMPAmmassariACozzi-LepriAAdherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than those receiving protease inhibitor-containing regimensAIDS20031771099110212700467
   PubMed Web of Science ®Google Scholar
• FlandrePPeytavinGMeifreddyVAdherence to antiretroviral therapy and outcomes in HIV infected patients enrolled in an induction/maintenance randomized trialAntivir Ther20027211312112212923
   PubMed Web of Science ®Google Scholar
• StoneVEJordanJTolsonJPerspectives on adherence and simplicity of HIV-infected patients on antiretroviral therapy. Self-report of the relative importance of multiple attributes of Highly Active Antiretroviral Therapy (HAART) regimens in predicting adherenceJ Acquir Immune Defic Syndr200436380881615213564
   PubMed Web of Science ®Google Scholar
• BoyleBJayaweeraDWittMDRandomization to once-daily stavudine extended release/lamivudine/efavirenz versus more frequent regimen improves adherence while maintaining viral suppressionHIV Clin Trials20089316417618547903
   PubMed Web of Science ®Google Scholar
• AiroldiMZaccarelliMBisiLOne-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjectsPatient Prefer Adherence2010411512520517472
   PubMed Web of Science ®Google Scholar
• GlassTRDe GeestSWeberRCorrelates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients. The Swiss HIV Cohort studyJ Acquir Immune Defic Syndr200641338539216540942
   PubMed Web of Science ®Google Scholar
• NguyenACalmyADelhumeauCA randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)AIDS201125121481148721593661
   PubMed Web of Science ®Google Scholar
• MurrayMGoodqinBHaginsDGallienSBrennanCMinSMeasuring patient satisfaction with HIV treatments: comparing dolutegravir with darunavir/r in the FLAMINGO studyPresented at: 20th International AIDS ConferenceJuly 20–25, 2014Melbourne, Australia Poster WEPE065
   Google Scholar
• WoodcockABradleyCValidation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change versionValue Health2006952033
   Web of Science ®Google Scholar
• WuGAbrahamTSaadNDolutegravir for the treatment of adult patients with HIV-1 infectionExpert Rev Anti Infect Ther201412553554424694091
   PubMed Web of Science ®Google Scholar